Étiquette : politique sanitaire

Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew, Kenneth W. Tupper and Beatriz C. Labate, 2014

Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew Kenneth W. Tupper, and Beatriz C. Labate Current Drug Abuse Reviews, 2014, 7, 71-80   Abstract : This article offers critical sociological and philosophical reflections on ayahuasca and other psychedelics as objects of research in medicine, health and human sciences. It situates 21st century scientific inquiry on ayahuasca in the broader context of how early modern European social trends and intellectual pursuits translated into new forms of empiricism and experimental philosophy, but later evolved into a form of dogmatism that convenienced the political suppression of academic inquiry into [...]

Lire la suite

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women, Elena Argento et al., 2018

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women Elena Argento, Melissa Braschel, Zach Walsh, M. Eugenia Socias and Kate Shannon Journal of Psychopharmacology, 2018, 1–7 DOI : 10.1177/0269881118798610   Abstract Background/aims : Given high rates of depression and suicide among marginalized women, and increasing calls to integrate trauma-informed biomedical and community-led structural interventions, this study longitudinally examines the potential moderating effect of psychedelic use on the relationship between other illicit drug use and suicide risk. Methods : Data (2010–2017) were drawn from a community-based, prospective open cohort of marginalized women in Vancouver, Canada. Extended Cox regression [...]

Lire la suite

Psychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy, James W.B. Elsey, 2017

Psychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy James W.B. Elsey Drug Science, Policy and Law, 2017, Vol 3, 1-11 DOI: 10.1177/2050324517723232   Abstract The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into the use of psychedelic drugs in healthy individuals, including neurobiological and subjective effects. In line with findings [...]

Lire la suite

LSD Psychotherapy by Stanislas GROF, 1997

LSD Psychotherapy Stanislas GROF Hunter House Ed., 1979   LIST OF CONTENTS 1. History of LSD Therapy The Discovery of LSD and its Psychedelic Effects Early Laboratory and Clinical LSD Research Therapeutic Experimentation With LSD Studies of Chemotherapeutic Properties of LSD LSD-Assisted Psychotherapy The Need for a Comprehensive Theory of LSD Therapy 2. Critical Variables in LSD Therapy Pharmacological Effects of LSD Personality of the Subject Personality of the Therapist or Guide Set and Setting of the Sessions 3. Psycholytic and Psychedelic Therapies with LSD : Towards an Integration of Approaches The Search for an Effective Technique of LSD Psychotherapy Advantages and Drawbacks of the Psycholytic Approach Pros and Cons of Psychedelic Therapy 4. Principles of LSD Psychotherapy The Preparation Period Psychedelic Sessions Integration [...]

Lire la suite

Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users, Genís Ona et al., 2019

Ayahuasca and Public Health : Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users Genís Ona, Maja Kohek, Tomàs Massaguer, Alfred Gomariz, Daniel F. Jiménez, Rafael G. Dos Santos, Jaime E. C. Hallak, Miguel Ángel Alcázar- Córcoles & José Carlos Bouso Journal of Psychoactive Drugs, 2019, DOI: 10.1080/02791072.2019.1567961   ABSTRACT Assessing the health status of ayahuasca users has been challenging due to the limitations involved in randomized clinical trials and psychometric approaches. The main objective of this study is the implementation of an approach based on public health indicators. We developed a self-administered questionnaire that was administered to long-term [...]

Lire la suite

Harm potential of magic mushroom use : A review, Jan van Amsterdam et al., 2011

Harm potential of magic mushroom use : A review Jan van AMSTERDAM, Antoon OPPERTHUIZEN, Wim van den BRINK Regulatory Toxicology and Pharmacology, 2011, 59, 423-429. Doi : 10.1016/j.yrtph.2011.01.006   Abstract In 2007, the Minister of Health of the Netherlands requested the CAM (Coordination point Assessment and Monitoring new drugs) to assess the overall risk of magic mushrooms. The present paper is an updated redraft of the review, written to support the assessment by CAM experts. It summarizes the literature on physical or psychological dependence, acute and chronic toxicity, risk for public health and criminal aspects related to the consumption of magic mushrooms. In the Netherlands, the [...]

Lire la suite

Medical Use of Cannabis in 2019, Kevin P. Hill, 2019

Medical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868   Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]

Lire la suite

Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962, Matthew ORAM, 2012

Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962 Matthew ORAM Journal of the History of Medicine and Allied Sciences, 2012, Volume 69, Number 2, 221-250. doi:10.1093/jhmas/jrs050   ABSTRACT. The decline in therapeutic research with lysergic acid diethylamide (LSD) in the United States over the course of the 1960s has commonly been attributed to the growing controversy surrounding its recreational use. However, research difficulties played an equal role in LSD psychotherapy’s demise, as they frustrated researchers’ efforts to clearly establish the efficacy of treatment. Once the Kefauver Harris Drug Amendments of 1962 introduced the requirement that proof of efficacy be established through controlled clinical [...]

Lire la suite

Ibogaine : A review – Chapter 1, Kenneth R. Alper, 2001

Ibogaine : A review - Chapter 1 Kenneth R. Alper The Alkaloids. Chemistry and Biology, 2001, 56,  38 pp DOI: 10.1016/S0099-9598(01)56005-8   I. Introduction, Chemical Properties, and Historical Time Line ..................... A. Introduction................................................................................................... B. Chemical Structure and Properties .............................................................. C. Historical Time Line ..................................................................................... II. Mechanisms of Action .................................................................................. A. Neurotransmitter Activities........................................................................... B. Discrimination Studies.................................................................................. C. Effects on Neuropeptides............................................................................... D. Possible Effects on Neuroadaptations Related to Drug Sensitization or Tolerance ....................................................................................................... III. Evidence of Efficacy in Animal Models........................................................ A. Drug Self-Administration .............................................................................. B. Acute Opioid Withdrawal .............................................................................. C. Conditioned Place Preference........................................................................ D. Locomotor Activity........................................................................................ E. Dopamine Efflux............................................................................................. IV Evidence of Efficacy and Subjective Effects in Humans .............................. A. Evidence of Efficacy........................................................................................ B. Subjective Effects ........................................................................................... V. Pharmacokinetics ........................................................................................... A. Absorption....................................................................................................... B. Distribution .................................................................................................... C. Metabolism .................................................................................................... D. Excretion [...]

Lire la suite

Price elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis, Michael Amlung et al., 2018

Price elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis Michael Amlung, Derek D. Reed, Vanessa Morris, Elizabeth R. Aston, Jane Metrik & James MacKillop Addiction, 2018, 114, 112–118 doi:10.1111/add.14437   ABSTRACT Background and Aims : The evolving legal status of cannabis world-wide necessitates evidence-based regulatory policies to minimize risks associated with cannabis misuse. A prominent concern is the impact legalization may have on the illegal cannabis market, including whether illegal cannabis will serve as a substitute for legal cannabis. Empirical data on this issue are virtually non-existent. This study used behavioral economics to investigate substitutability of legal and illegal cannabis in legalized catchment areas [...]

Lire la suite